| pubmed-article:1605590 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C0332307 | lld:lifeskim |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C0553257 | lld:lifeskim |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C0031676 | lld:lifeskim |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C0002679 | lld:lifeskim |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C0441655 | lld:lifeskim |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C0600688 | lld:lifeskim |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C0456603 | lld:lifeskim |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C1533691 | lld:lifeskim |
| pubmed-article:1605590 | lifeskim:mentions | umls-concept:C0524527 | lld:lifeskim |
| pubmed-article:1605590 | pubmed:issue | 2 | lld:pubmed |
| pubmed-article:1605590 | pubmed:dateCreated | 1992-7-14 | lld:pubmed |
| pubmed-article:1605590 | pubmed:abstractText | We studied the influence of the lipid/amphotericin B (AMB) ratio and the phospholipid type on the in vitro renal cell toxicity and antifungal efficacy of lipid-associated AMB (L-AMB). L-AMB was prepared at one of two different lipid/AMB ratios (1 and 40) by incubating AMB with empty small unilamellar vesicles, made from one of three different phospholipids: dipalmitoyl-, dimirystoyl-, and distearoylphosphatidylcholine (DPPC, DMPC, and DSPC, respectively). Renal cell toxicity, investigated through an assessment of the Na-dependent uptake of phosphate by proximal tubular cells, and fungicidal effect against Candida albicans were studied after 1 h of treatment at 37 degrees C. The amount of unbound AMB present in each L-AMB formulation was studied by use of circular dichroism. At a lipid/AMB ratio of 40, the three lipidic formulations were not toxic for renal cells but were less effective against C. albicans than AMB; however, DSPC-AMB, which contained 50% unbound AMB, was more effective against C. albicans than DPCC-AMB or DMPC-AMB, containing 0 and 13% unbound AMB, respectively. At a lipid/AMB ratio of 1, the antifungal effects of L-AMB and AMB were similar, whatever the phospholipid used, but only DMPC-AMB remained highly protective against AMB renal cell toxicity, despite the presence of the same amount of unbound AMB (50%) in DMPC-AMB and DPPC-AMB. We conclude that the in vitro activities and renal cell toxicities of different L-AMB formulations are influenced by the phospholipid type and the lipid/AMB ratio. The optimal ratio depends on the phospholipid itself. At a lipid/AMB ratio of 40, the antifungal activity depends mainly on the amount of unbound AMB in the formulation. At a lipid/AMB ratio of 1, the renal cell toxicity also depends on the fluidity of the phospholipid. | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:commentsCorrections | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:language | eng | lld:pubmed |
| pubmed-article:1605590 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:1605590 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:1605590 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:1605590 | pubmed:issn | 0066-4804 | lld:pubmed |
| pubmed-article:1605590 | pubmed:author | pubmed-author:CarbonCC | lld:pubmed |
| pubmed-article:1605590 | pubmed:author | pubmed-author:BolardJJ | lld:pubmed |
| pubmed-article:1605590 | pubmed:author | pubmed-author:YeniPP | lld:pubmed |
| pubmed-article:1605590 | pubmed:author | pubmed-author:JolyVV | lld:pubmed |
| pubmed-article:1605590 | pubmed:author | pubmed-author:Saint-JulienL... | lld:pubmed |
| pubmed-article:1605590 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:1605590 | pubmed:volume | 36 | lld:pubmed |
| pubmed-article:1605590 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:1605590 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:1605590 | pubmed:pagination | 262-6 | lld:pubmed |
| pubmed-article:1605590 | pubmed:dateRevised | 2009-11-18 | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:meshHeading | pubmed-meshheading:1605590-... | lld:pubmed |
| pubmed-article:1605590 | pubmed:year | 1992 | lld:pubmed |
| pubmed-article:1605590 | pubmed:articleTitle | Influence of phospholipid/amphotericin B ratio and phospholipid type on in vitro renal cell toxicities and fungicidal activities of lipid-associated amphotericin B formulations. | lld:pubmed |
| pubmed-article:1605590 | pubmed:affiliation | Laboratoire d'Etude des Traitements Antiinfectieux, Faculté Xavier Bichat, Université Paris 7, France. | lld:pubmed |
| pubmed-article:1605590 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:1605590 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1605590 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1605590 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1605590 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1605590 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:1605590 | lld:pubmed |
